Update on lung cancer from the annual meeting of the American society of clinical oncology 2012

被引：0
作者：
Sacha I. Rothschild
Oliver Gautschi
机构：
[1] Department Internal Medicine Medical Oncology, University Hospital Basel, 4031 Basel
[2] Medical Oncology, Luzerner Kantonsspital, Lucerne
来源：
memo - Magazine of European Medical Oncology | 2012年 / 5卷 / 4期
关键词：
ASCO; Chemotherapy; Maintenance; Nonsmall cell lung cancer;
D O I：
10.1007/s12254-012-0050-z
中图分类号：
学科分类号：
摘要：
The American Society of Clinical Oncology (ASCO) held its annual meeting in Chicago, Illinois (USA) from June 1-5, 2012. In the lung cancer track, several hundreds of abstracts were presented. The following article will give an overview on some interesting and relevant abstracts. Beside new drugs, the role of biomarker, and maintenance therapy, we will also discuss issues on early-stage disease. © 2012 Springer-Verlag Wien.
引用
收藏
页码：253 / 258
页数：5
相关论文
共 35 条
  • [21] Yeh T.C., Marsh V., Bernat B.A., Ballard J., Colwell H., Evans R.J., Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor, Clin Cancer Res, 13, 5, pp. 1576-1583, (2007)
  • [22] Davies B.R., Logie A., McKay J.S., Martin P., Steele S., Jenkins R., AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models, Mol Cancer Ther, 6, 8, pp. 2209-2219, (2007)
  • [23] Janne P.A., Shaw A.T., Pereira J.R., Jeannin G., Vansteenkiste J., Barrios C.H., Et al., Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC), J Clin Oncol., 30, SUPPL., (2012)
  • [24] Brahmer J.R., Horn L., Antonia S., Spigel D.R., Gandhi L., Sequist L.V., Et al., Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC), J Clin Oncol., 30, SUPPL., (2012)
  • [25] Hellerstedt B.A., Edelman G., Vogelzang N.J., Kluger H.M., Yasenchak C.A., Shen X., Et al., Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT), J Clin Oncol., 30, SUPPL., (2012)
  • [26] Kim D.-W., Ahn M.-J., Shi Y., De Pas T.M., Yang P.-C., Riely G.J., Et al., Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC), J Clin Oncol., 30, SUPPL., (2012)
  • [27] Camidge D.R., Kono S.A., Flacco A., Tan A.C., Doebele R.C., Zhou Q., Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment, Clin Cancer Res., 16, 22, pp. 5581-5590, (2010)
  • [28] Salido M., Pijuan L., Martinez-Aviles L., Galvan A.B., Canadas I., Rovira A., Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer, J Thorac Oncol., 6, 1, pp. 21-27, (2011)
  • [29] Doebele R.C., Pilling A.B., Aisner D.L., Kutateladze T.G., Le A.T., Weickhardt A.J., Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer, Clin Cancer Res., 18, 5, pp. 1472-1482, (2012)
  • [30] Camidge D.R., Skokan M., Kiatsimkul P., Helfrich B., Schulte N., Maxson D., Et al., Native and rearranged ALK copy number and rearranged ALK cell count in NSCLC: Implications for ALK inhibitor therapy, J Clin Oncol., 30, SUPPL., (2012)
1234